S276: POVETACICEPT (ALPN-303), A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF AUTOIMMUNE CYTOPENIAS AND OTHER ANTIBODY-RELATED DISEASES
Main Authors: | Stacey Dillon, Rupert Davies, Jason Lickliter, Kristi Mclendon, Kristi Kristi L. Manjarrez, Bs, Alina Smith, Krystalyn Hudson, Lori Blanchfield, Russel Sanderson, Allison Chunyk, Tiffany Blair, Amanda Enstrom, Hany Zayed, Stanford Peng |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000968016.33010.55 |
Similar Items
-
PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)
by: Catherine M Broome, et al.
Published: (2023-08-01) -
PO.6.131 A randomized, double-blind, placebo controlled study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-303, a potent dual baff/april inhibitor, in adult healthy volunteers
by: A Smith, et al.
Published: (2022-10-01) -
P104 Upregulation of both APRIL and BAFF in systemic lupus erythematosus suggests non-redundant roles, further revealed by potent dual inhibition with povetacicept (TACI vTD-Fc; ALPN-303)
by: Amanda Enstrom, et al.
Published: (2024-03-01) -
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
by: Karin Kannel, et al.
Published: (2015-01-01) -
Sinetron Leads to Negotiation of Identity: Christian Identity and the Representation of Religion in Indonesian Popular Culture
by: Kristi Kristi
Published: (2019-01-01)